Education:

1978-1983 MD, in Medicine, Second Military Medical University

1985-1988 MMedSc, in Clinical Immunology, Second Military Medical University

1990-1993 PhD, in Clinical Immunology, Flinders University of South Australia

Professional Positions:

1983-1985 Resident Medical Officer, Department of Medicine, Changzheng Hospital, Second Military Medical University, China

1988-1990 Attending Doctor and Lecturer, Department of Medicine, Changzheng Hospital, Second Military Medical University, China

1994-1996 The National SIDS Foundation Fellow and Honorary Senior Registrar, Department of Clinical Immunology, Flinders Medical Centre, Flinders University of South Australia, Australia

1996-2007 RO, SRO, NHMRC Fellow, Queensland Institute of Medical Institute, Australia

2002- now Founder Chair and Professor, Department of Rheumatology and Immunology Shanghai Changzheng Hospital, Second Military Medical University, China

2009-2015 Professor, University of Queensland, Australia

2015- now Chairman, Department of Internal Medicine, Shanghai Changzheng Hospital, Naval Medical University, China

2016- now Professor (Tenured) School of Medicine, Tsinghua University

2017- now Founder Executive Vice Dean, School of Clinical Medicine, Tsinghua University

2023- now Deputy Director, National Key Laboratory for Immunity and Inflammation, Shanghai, China

Research Areas:

Translational research on innovative diagnosis and treatment of autoimmune diseases. In the diagnostic field, we pioneered the discovery that different HLA-B27 subtypes have significant importance in the diagnosis of ankylosing spondylitis (AS), opening up new directions for early and precise diagnosis. This research was reviewed as a major breakthrough in the field. Building on this, the project innovatively integrated the largest-scale AS genome-wide information internationally (over 30,000 multi-ethnic patients), developed, proposed, and validated a new Polygenic Risk Score method for AS based on genome-wide data. This is the first groundbreaking research internationally to successfully use genetic data to construct a method model for early diagnosis and prediction of rheumatic immunological diseases. In the treatment field, we were the first internationally to successfully use allogeneic universal CAR-T cells derived from healthy individuals to treat rheumatic diseases. We were among the earliest to reveal TH17 cells' involvement in AS pathogenesis. This promoted anti-IL-17 antibody drugs to become the mainstream product for global AS treatment. On this basis, we led and participated in 32 international multicenter Phase II and III clinical trials, including the world's first clinical development of small molecule compound drugs, the world's first Phase III clinical trial of IL-17A/F bispecific antibodies, and the world's first head-to-head Phase III clinical trial comparing a biosimilar with the original adalimumab.

In summary, Prof Xu’s research has encompassed many fields, including but not restricted to immunology, molecular biology, human genetics and vaccinology. Currently, his major research interest is in the area of pathogenesis of rheumatic diseases. His research over last 10 years resulted in several major publications in Cell, Nature, Nature Genetics, Arthritis & Rheumatism, Annals of Rheumatic Diseases, lancet Rheumatology, The Journal of Immunology, Proc Natl Acad Sci USA, The Journal of Experimental Medicine, and Annual Review of Immunology.

Honors and Awards:

2024 Roche Clinical Investigator Award

2024 “Tan Jiazhen” Clinical Medicine Award

2024 Shanghai Clinical Innovation Award (1st Prize)

2022 "Benevolent Physician - Shanghai Outstanding Specialist Physician" Award

2022 Science and Technology Advanced Award (1st Prize), China Ministry of Education

2022 National "People's Distinguished Doctor · Outstanding Achievement" title Award

2019 The State Council Special Allowance

2019 Shanghai Science and Technology Advanced Award (1st Prize), Shanghai Municipal Government

2014 Chief Scientist, National Program on Key Basic Project (973 Program), China Ministry of Science and Technology

2013 Shanghai Medical Science and Technology Advanced Award (1st Prize), Shanghai Medical Association

2012 National Professorship, China Central Government for “National Talent Recruitment ”

2010 Shanghai Key Leadership, awarded by Shanghai Municipal Government

2008 Distinguished Leading Research Scholar in Shanghai, awarded by Shanghai Science and Technology Commission

Selected Publications:

1.Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. (2024).Allogeneic CD19-targeted CAR-T therapy in severe myositis and systemic sclerosis achieved durable remission and reversed extensive fibrotic damages. Cell. doi: 10.1016/j.cell.2024.06.027

2.Wang T, Sternes PR, Guo XK, Zhao H, Xu C, Xu H. (2024). Autoimmune diseases exhibit shared alterations in the gut microbiota. Rheumatology. 63, 856-865.

3.Liu Y, Zhang Z, Kang Z, Zhou X, Liu S, Guo S, Jin Q, Li T, Zhou L, Wu X, Wang YN, Lu L, He Y, Li F, Zhang H, Liu Y, Xu H. (2023). Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus. Ann Rheum Dis. 82, 1444-1454

4.Li JX, Wu X, Lee YH, Xu H. (2023). West Meets East in Genetics of Ankylosing Spondylitis. Int J Rheum Dis. 26, 2122-2126

5.Guo XK, Wang J, Vincent P. H, Liu J, Xu H, Hu X. (2023). Interactions between host and intestinal crypt-resided biofilms are controlled by epithelial fucosylation. Cell Rep. 42, 112754

6.Kang Z, Wang J, Meng T, Zhang H, Xu D, Gong H, Chang Z, Li Z, Cui X, Xiao J, Qureshi AI., Zhou W, Liu J, Xu H. (2023). Pericytes may facilitate SARS-CoV-2 entry into the nervous system. Journal of Bio-X Research. 6, 23-36

7.Tian H, Li T, Wang Y, Lu H, Lin L, Wu X, Xu H. (2023). The correlations between C-reactive protein and MRI-detected inflammation in patients with axial spondyloarthritis: a systematic review and meta-analysis. Clin Rheumatol. 42, 2397-2407

8.Cai B, Lu H, Ye Q, Xiao Q, Wu X, Xu H. (2023). Identification of potent target and its mechanism of action of Tripterygium wilfordii Hook F in the treatment of lupus nephritis. Int J Rheum Dis. 26, 1529-1539

9.Li Y, Li B, Wang G, Su J, Qiao Y, Ma C, Wang F, Zhu J, Li J, Zhang H, Liu K, Xu H. (2023). Engineered protein and Jakinib nanoplatform with extraordinary rheumatoid arthritis treatment. Nano Res. 16, 11197−11205

10.Wang X, Zhu L, Ying S, Liao X, Zheng J, Liu Z, Gao J, Niu M, Xu X, Zhou Z, Xu H. (2023). Increased RNA Editing Sites Revealed as Potential Novel Biomarkers for Diagnosis in Primary Sjögren’s Syndrome. J Autoimmun. 138, 103035

11.Jin Q, Liu Y, Zhang Z, We X, Chen Z, Tian H, Kang Z, Wu X, Xu H. (2023). MYC Promotes Fibroblast Osteogenesis by Regulating ALP and BMP2 to Participate in Ectopic Ossification of Ankylosing Spondylitis. Arthritis Res Ther. 25, 28

12.Chi X, Huang M, Tu H, Zhang B, Lin X, Xu H, Dong C, Hu X. (2023). Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections. Sci China Life Sci. 66, 1482-1517.

13.Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Bosch F, Vaux T, Xu H. (2023). Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomized Controlled Trials. Ann Rheum Dis. 82, 515-526

14.Huang M, Xu H. (2022). Genetic susceptibility to autoimmunity-current status and challenges. Adv Immunol. 156, 25-54

15.Ye L, Li W F, Shao J, Xu Z, Ju J, Xu H. (2022). Fighting Omicron epidemic in China: real-world big data from Fangcang Shelter Hospital during the outbreak in Shanghai 2022. J Infection. 85, 436-480

16.Wu X, Geng X, Shang Z, Wang Z, Lu H, Liu W, Xu H. (2022). Post-traumatic stress disorder in patients with rheumatic disease during the COVID-19 outbreak: a cross-sectional case-control study in China. BMJ Open. 12, e049749.

17.Wu X, Xu H, Dong C. (2022). Beyond interleukin-17-targeted therapy: Complexity of environment-genetics-immunology needs to be addressed. Chinese Med J-Peking. 135, 511-512

18.Ye L, Zhou L, Bian J, Zhao J, Li T, Wu X, Xu H. (2022). Disease activity guided stepwise tapering but not discontinuation of biologics is a feasible therapeutic strategy for patients with ankylosing spondylitis: real-world evidence. Adv Ther. 39, 1393-1402

19.Wang T, Guo X K, Xu H. (2021). Disentangling the progression of nonalcoholic fatty liver disease in the human gut microbiota. Front Microbiol. 12, 728823

20.Lu H, Wang Y, Wang X, Wu X, Zhou L, Sheng R, Tian H, Li T, Xu H. (2021). Yisaipu® provide AS patients with an economical therapeutic option while original biologicals are more advantageous in the COVID-19 epidemic situation. Front Pharmacol. 12, 692768

21.Zhou L, Li T, Wu X, Lu H, Lin L, Ye L, Yin J, Zhao J, Wang X, Bian J, Xu H. (2021). Assessment of neuropathic pain in Ankylosing Spondylitis: prevalance and characteristics. Pain Ther. 10, 1467-1479

22.Wu X, Wang G, Zhang L, Xu H. (2021). Genetics of Ankylosing Spondylitis – focusing on the ethnic difference between East Asia and Europe. Front Genet. 12, 671682

23.Li Z, Wu X, Leo PJ, Guzma L, Akkoc N, Breban M, MacFarlane G, Mahmoudi M,Marzo-Ortega H, Anderson L, Wheeler L, Chou CT, Harrison AA, Stebbings S, Jones GT, Bang SO, Wang G, Song J, Lin L, Li M, Wei JZZ, Martin NG, Wright MJ, Lee M, Wang Y, Zhan J, Zhang JS, Wang XB, Jin ZB, Weisman MH, Gensler LS, Ward MM, Rahbar MH, Diekman L, Kim T, Reveille JD, Wordsworth PB, Xu H, Brown MA. (2021). Polygenic risk scores have high diagnostic capacity in ankylosing spondylitis. Ann Rheum Dis. 80, 1168-1174

24.Brown MA, Xu H, Li Z. (2020). Genetics and the axial spondyloarthritis spectrum. Rheumatology. 59, iv58-iv66

25.Wu X, Zheng H, wang C, Xu S, Gao G, Li M, Wang Z, Jiang C, Dou Z, Xiao Y, Xie K, Wang S, Xu H. (2020). A novel privacy-preserving federated genome-wide association study framework and its application in identifying potential risk variants in ankylosing spondylitis. Brief Bioinfirm. 22, bbaa090

26.Zhang H, Kang Z, Gong H, Xu D, Wang J, Li ZX, Li ZF, Cui XG, Xiao JR, Zhan J, Meng T, Zhou W, Liu JM, Xu H. (2020). Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 69, 1010-1018

27.Wang G, Kim TH, Li ZX, Cortes.A, Kim K, Bang SY, Leo P, Brown MA, Xu H. (2020). MHC associations of ankylosing spondylitis in East Asians are complex and involve non-HLA-B27 HLA contributions. Arthritis Res Ther. 22, 74

28.Shi XY, Wang G, Li T, Li Z, Leo P, Liu Z, Wu G, Zhu H, Zhang Y, Li D, Gao L, Yang L, Wang W, Liao J, Wang J, Zhou S, Wang H, Li X, Gao J, Zhang L, Shu X, Li D, Li Y, Chen C, Zhang X, Reutens D, Bartlett P, Brown MA, Zou LP, Xu H. (2020). Identification of susceptibility variants to benign childhood epilepsy with centro-temporal spikes (BECTS) in Chinese Han population. EBioMedicine. 57, 102840

29.Liu Y, Wu X, Ye L, Xu H. (2020). Successful treatment of a patient with kasabach–merritt syndrome and multiple giant hepatic hemangiomas. J Int Med Res. 48, 030006051989835

30.Xu H, Yin J. (2020). HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis. Best Pract Res CL RH. 33, 101499

31.Li T, Liu Y, Sheng R, Yin J, Wu X, Xu H. (2020). Correlation between chronic pain acceptance and clinical variables in ankylosing spondylitis and its prediction role for biologics treatment. Front Med (Lausanne). 7, 17

32.Yin J, Sternes P, Wang M, Song J, Morrison M, Li T, Zhou L, Wu X, He F, Zhu J, Brown MA, Xu H. (2020). Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 79, 132-140

33.Zhang W, Zhang H, Liu S, Xia F, Kang Z , Zhang Y, Liu Y, Xiao H, Chen L , Huang C, Shen N, Xu H, Li F. (2019). Excessive CD11c(+)T bet(+) B cells promote aberrant T-FH differentiation and affinity-based germinal center selection in lupus. P Natl Acad Sci USA. 116, 18550-18560

34.Wu X, Lu H, Xu H. (2019). Andersson lesion in ankylosing spondylitis misdiagnosed as spinal tuberculosis: two cases. Int J Clin Exp Med. 12, 14001-14004

35.Li T, Zhou L, Zhao H, Song J, Wang X, Liu S, Xu H. (2019). Fatigue in ankylosing spondylitis is associated with the psychological factors and brain gray matter. Front Med (Lausanne). 6, 271

36.Xu H, Li Z, Wu J, Xing Q, Shi G, Li J, Liu X, Wu L, Li X, Tan W, He D, Bi L, Li H, Xiao Z, Shuai Z, Li X, Wang Y, Luo L, Zheng Y, Xiao W, Wu X, Zhou L, Li T, Qian L, Zhou H, Lu S, Zheng S, Xiong Y, Wang X, Wang Y, Wu X. (2019). IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomized, double-blind, phase 3 equivalence trial. Lancet Rheum. 1, e35–43

37.Liu Y, Zhang Z, Jin Q, Liu Y, Kang Z, Huo Y, He Z, Feng X, Yin J, Wu X, Wang H, Xu H. (2019). Hyperprolactinemia is associated with a high prevalence of serum autoantibodies, high levels of inflammatory cytokines and an abnormal distribution of peripheral B cell subsets. Endocrine. 64, 648-656

38.Khanniche A, Zhou L, Jiang B, Song J, Jin Y, Yin J, Wang S, Ji P, Shen H, Wang Y, Xu H. (2019). Restored and enhanced memory T cell immunity in rheumatoid arthritis after TNFα blocker treatment. Front Immunol. 10, 887

39.Wu X, Sheng X, Sheng R, Lu H, Xu H. (2019). Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis. Frontiers of Medicine. 13, 411-419

Complete list of publications: https://www.scopus.com/authid/detail.uri?authorId=15078044400

https://www.webofscience.com/wos/author/record/AAB-2902-2021